NeuroRx submits request for Emergency Use Authorization with the US FDA for aviptadil in the treatment of patients with critical COVID-19 and respiratory failure who have exhausted approved therapy

The submission is based on a case-control study conducted in a single ICU comparing aviptadil (n=21) to maximal standard of care treatment (n=30), showing improvements in survival, recovery from respiratory failure, and other clinical parameters.

Source:

Biospace Inc.